Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


ASAM and the AMA Announce Innovative Payment Model to Improve Treatment of Opioid Use Disorder


 

Washington, D.C. - The American Society of Addiction Medicine (ASAM) and the American Medical Association (AMA) jointly announced today the release of a concept paper detailing a groundbreaking alternative payment model (APM) that could revolutionize how patients with opioid use disorder are treated.

The new payment model, known as Patient-Centered Opioid Addiction Treatment (P-COAT), is expected to increase the number of patients with opioid use disorder who are able to lead satisfying, productive lives through successful management of their condition while also reducing health care spending on costs associated with addiction, such as emergency department visits and hospitalizations.

"We have seen significant increases in the rate of individuals dying from opioid poisonings across the United States once again this year," said Kelly J. Clark, MD, MBA, DFAPA, DFASAM, president of ASAM. "At the same time, millions of individuals across the country continue to lack access to treatment due to insurance reimbursement and coverage barriers. I am proud of the AMA-ASAM APM Working Group for developing a framework that seeks to address these issues."

The new payment model seeks to increase utilization of and access to medications for the treatment of opioid use disorder by providing the appropriate financial support to successfully treat patients and broaden the coordinated delivery of medical, psychological, and social support services. P-COAT is also designed to support office-based opioid treatment in order to facilitate coordination between multiple treatment providers. Previously, payment for these services has been segregated, which contributes to patient difficulties receiving comprehensive care.

"Arbitrary limitations on effective, comprehensive treatment are stymying physician efforts to treat patients with opioid use disorder," said Patrice A. Harris, MD, MA, chair of the AMA Opioid Task Force. "This new tool will remove a brick in the wall that prevents patients from accessing needed treatment. Eventually, this wall will be torn down. Until then, we must continue fighting for our patients and remove arbitrary barriers to care."

The P-COAT APM is based on a wealth of research showing that medications combined with psychosocial supports is effective in treating individuals with opioid use disorder. Unfortunately, the current physician payment system offers little support for the coordination of behavioral, social and other support services that patients being treated for opioid use disorder need in addition to their medication. Non-face-to-face services - such as phone calls and email consultations with patients - in addition to better coordination between specialists, outpatient treatment programs and other health providers such as emergency rooms, are essential to the delivery of effective, evidence-based treatment to the individuals who need it.

"The current physician reimbursement structure does not account for all the services that patients with an opioid use disorder need to progress to successful treatment and recovery," said Shawn Ryan, MD, MBA, ABEM, ABAM, FASAM, chair of the AMA-ASAM APM Working Group and ASAM's Payer Relations Committee. "While we know that a combination of medication and psychosocial support systems is the evidence-based standard for treatment, we continue to find that patients are not able to access treatment due to limited or non-existent insurance coverage. We hope that today's announcement will begin a national conversation with insurers and policymakers about what it takes for successful treatment and recovery."

The APM announced today is the result of extensive development and review. ASAM and the AMA are now seeking physician practices and insurers interested in pilot testing the new payment model. Anyone interested in participating in P-COAT should submit their contact information here.

For more information about the P-COAT APM, please review ASAM's issue brief here.

The complete P-COAT APM is available here.

 
Share:

Related Articles:


Recent Articles

Ascension Saint Thomas Heart First in State, Region, Ascension to Offer Novel Medical Technique

On February 9, Ascension Saint Thomas Hospital West became the first Ascension hospital in the country and the only medical facility in Tennessee to offer intracoronary brachytherapy, a procedure that helps improve chest pain in patients with stents that have re-narrowed (sometimes called "collapsed") and reduces the chance of them narrowing again in the future.

Read More

Functional Seizures Associated with Stroke, Psychiatric Disorders in Electronic Health Records Study

In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.

Read More

New survey shows minorities, children missing cancer screenings and vaccinations

52% of adults missing lifesaving screenings to prevent cancer are not rescheduling them

Read More

Sarah Cannon Cancer Institute at Swedish Medical Center Sheds New Light on Brain Tumors

Neurosurgery is a complex and intricate process, and it is important to continuously refine and seek innovative techniques to make it safer, gentler and more precise and effective.

Read More

Study Finds Recommended ICU Sedatives Equally Safe, Effective

Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

Read More

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Read More

DRUG COMPANIES URGED TO PROVIDE DISCOUNTS TO 340B COMMUNITY PHARMACIES

Yesterday, counsel for the American Hospital Association and the five other national groups and three individual hospital systems that sued the Department of Health and Human Services (HHS) over its failure to halt drug company actions that undermine the 340B drug pricing program sent letters demanding that the offending drug companies immediately halt their illegal activities.

Read More

Study Shows Drastic Increases in Opioid-Affected Births

The rate of mothers who had an opioid-related diagnosis when delivering their baby increased by 131% from 2010-2017, as the incidence of babies diagnosed with drug withdrawal, known as neonatal abstinence syndrome (NAS), increased by 82% nationally during that same time period.

Read More

Case Management: Enhancing Revenue, Care Transitions and Patient Outcomes throughout the Hospital System

The importance of hospital and health system case management has grown exponentially over the past 10 years and is now getting attention from leaders throughout the healthcare industry.

Read More

TennCare Block Grant Waiver Approved

More than a year after submitting Amendment 42 to the Centers for Medicare and Medicaid Services (CMS) requesting a waiver to increase flexibility in the administration of the state's Medicaid program, Tennessee has received an affirmative nod to move forward.

Read More

Email Print
 
 

 

 


Tags:
Addiction, American Society of Addiction Medicine, Opioids, P-COAT, Patient-Centered Opioid Addiction Treatment
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: